| Summary: | 碩士 === 國立屏東科技大學 === 動物疫苗科技研究所 === 97 === CpG oligodeoxynucleotide (ODN) that has been demonstrated to evoke a spectrum of TH1 immune responses in mammalian cells is an non-particulate adjuvant, and spieces-specific. Bovine mastitis, inflammation caused by the invasion of pathogenic bacteria into the mammary gland, is one of the most costly diseases in dairy industry. Staphylococcus aureus (S. aureus) and coliform bacteria are the most frequently isolated species from mastitic samples. Numerous attempts have been made to develop a vaccine against mastitis in the past decades, but the results were not satisfactory. The efficacy of a vaccine can be dramatically affected by its adjuvant. A bovine specific CpG ODN fragment was previously identified, and its immunostimulatory effects when being used as an adjuvant were evaluated in a keyhole limpet hemocyanin (KLH) vaccine. In trial 1, the results reveal that both the titer and persistence of KLH-specific antibodies, in serum (IgG, IgG1, IgG2, and IgM) and in whey (expect IgG2), as well as the production of IFN- were significantly (P < 0.05) increased in cows vaccinated with KLH and CpG ODN.
Therefore, we proposed that CpG ODN has the potential to be used as the adjuvant in vaccines for bovine. A quadrovalent mastitis vaccine containing three strains of S. aureus (T5, T8 and Smith compact) and E. coli J5 formulated with CpG ODN was designed for monitoring on immune parameters in trial 2. The results reveal not only the titer and persistence of antigens-specific antibodies, in serum (IgG and IgG1) and in whey (IgG, IgG1, and IgM) as well as the production of IFN- and IL-2, were significantly (P < 0.05) increased in cows vaccinated with antigen and CpG ODN, but the ability of specific antibody to enhance phagocytosis of specific bacteria by polymorphonuclear neutrophils (PMN). Taken together, in this study we suggest bovine specific CpG ODN fragment has the potential to be used as the adjuvant in vaccines for bovine. Further research will be required to study a new vaccine strategy with CpG adjuvant and antigens.
|
|---|
